We are a group of privately held biotech companies specialized in the development of innovative biopharmaceutical drugs, proteins and peptides, for the treatment of metabolic diseases and rare diseases.

American Diabetes Association, 75th scientific sessionsJune 5-9, 2015, Boston MA, USA
Bio International ConventionJune 15-18, 2015, Philadelphia, PA, USA

Program: AZP-531, unacylated ghrelin analog, for the treatment of the Prader-Willi syndrome and type 2 diabètes

 

Status: clinical Phase II - Unpartnered

Program: Pegcrisantaspase (Asparec®, JZP-416), PEGylated recombinant L-asparaginase for the treatment of acute lymphoblastic leukemia

 

Status: clinical Phase II/III – Partnered (Jazz Pharmaceuticals)

Program: I-HBD1, peptide with bone anabolic properties for the treatment of osteoporosis and other bone diseases

 

Status: Lead optimization – unpartnered